| epirubicin / Generic mfg. |
ChiCTR-IPR-16008631: A randomized controlled study of comparing the efficacy and safety of Pegylated liposmal doxorubicin, Epirubicin and Doxorubicin in Diffuse large B cell lymphoma |
|
|
| Not yet recruiting | 4 | 225 | | R-CDOP protocol ;R-CEOP protocol ;R-CHOP protocol | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-finacing | Diffuse large B cell lymphoma | | | | |
| Active, not recruiting | 4 | 290 | RoW | Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Ruijin Hospital | Diffuse Large B-cell Lymphoma | 10/22 | 12/24 | | |
NCT00005584: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 3 | 1649 | Europe | bleomycin sulfate, ABVD regimen, BEACOPP regimen, epirubicin hydrochloride, prednisone, vinblastine sulfate, radiation therapy | European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, UNICANCER | Lymphoma | 05/04 | | | |
NCT05075460: Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 3 | 107 | RoW | Tucidinostat, Azacitidine combined with CHOP | Peking Union Medical College Hospital | T-cell Lymphoma | 05/24 | 10/24 | | |
NCT05164770: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 160 | RoW | Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX | Shandong Provincial Hospital | High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma, B-cell Non Hodgkin Lymphoma, Mantle Cell Lymphoma | 12/23 | 12/24 | | |
NCT05097443: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies | Shandong Provincial Hospital | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma | 12/23 | 12/24 | | |
NCT05678933: AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH |
|
|
| Enrolling by invitation | 3 | 200 | RoW | Azacitidine, Chidamide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Tianjin Medical University Cancer Institute and Hospital | Peripheral T-cell Lymphoma Targeted Therapy | 12/27 | 12/29 | | |
NCT04899570: Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Zanubrutinib, BRUKINSA, Rituximab, Rituxan, Cyclophosphamide, Epirubicin, Vindesine, Prednisone | Peking Union Medical College Hospital | Intravascular Large B-Cell Lymphoma | 04/23 | 04/25 | | |
NCT04214626: R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Rituximab, RiTUXimab Injection, Lenalidomide, Lenalidomide capsule, Cyclophosphamide, Cyclophosphamide Injection, Epirubicin, Epirubicin hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product, Methotrexate, Methotrexate Injectable Solution | Henan Cancer Hospital | Diffuse Large B Cell Lymphoma | 11/23 | 01/25 | | |
| Recruiting | 2 | 52 | RoW | Azacitidine in combination with R-CHOP | The First Affiliated Hospital of Xiamen University, Jiangsu Provincial People's Hospital, Sun Yat-sen University, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital | DLBCL - Diffuse Large B Cell Lymphoma, TP53 | 05/25 | 05/25 | | |
NCT04067037: Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | Camrelizumab, SHR-1210, Epirubicin, Epirubicin hydrochloride, Vincristine, Oncovin, Dacarbazine | Henan Cancer Hospital | Classical Hodgkin Lymphoma | 06/24 | 12/24 | | |
NCT04433156: VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | Bortezomib, Bortezomib Injection, Rituximab, RiTUXimab Injection, Epirubicin, Epirubicin hydrochloride, Cyclophosphamide, Cyclophosphamide Injection, Prednisone, Prednisone Oral Product | Henan Cancer Hospital | Marginal Zone Lymphoma | 12/23 | 04/25 | | |
NCT04668365: Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma |
|
|
| Recruiting | 2 | 59 | RoW | Rituximab, RiTUXimab Injection, Zanubrutinib, Zanubrutinib Pill, Cyclophosphamide, Cyclophosphamide Injection, Epirubicin, Epirubicin Injection, Vincristine, Vincristine Injection, Prednisone, Prednisone Pill | Henan Cancer Hospital | Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation | 12/23 | 12/25 | | |
NCT05290090: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL |
|
|
| Recruiting | 2 | 31 | RoW | Rituximab, Lenalidomide, Zanubrutinib and RCHOP, BGB-3111 | Zhejiang Cancer Hospital | Diffuse Large B Cell Lymphoma | 06/24 | 12/25 | | |
NCT05887726: Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors |
|
|
| Not yet recruiting | 2 | 30 | RoW | Zanubrutinib, Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone | Liaoning Tumor Hospital & Institute | Diffuse Large B Cell Lymphoma | 08/24 | 08/25 | | |
NCT05572983: Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype |
|
|
| Recruiting | 2 | 47 | RoW | Chidamide combined with CHOP, Induction treatment, Chidamide, Maintenance treatment | Sun Yat-sen University | Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | 09/24 | 09/26 | | |
NCT05933967: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 31 | RoW | Orelabrutinib+R-CHOP | Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Nanchang University | The First Affiliated Hospital of Nanchang University | 12/24 | 12/26 | | |
NCT02987244: Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | Chidamide, epidaza, Cyclophosphamide, Epirubicin, Vindesine, Etoposide, Prednisone | Peking Union Medical College Hospital, Chinese PLA General Hospital, Peking University First Hospital, Peking University Third Hospital, Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital | T Cell Non-Hodgkin's Lymphoma | 03/20 | 03/23 | | |
NCT06421948: Linperlisib Combined With Chidamide in Patients With PTCL |
|
|
| Recruiting | 1/2 | 100 | RoW | Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone | Yanyan Liu | Peripheral T-cell Lymphoma | 12/25 | 05/26 | | |
| No Longer Available | N/A | | Europe | CEOP/IMVP-Dexa chemotherapy | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lymphoma | | | | |
